- Home
- CCEL vs ARMP Comparison
CCEL vs ARMP Comparison
Compare CCEL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- ARMP
- Stock Information
- Founded
- CCEL 1989
- ARMP N/A
- Country
- CCEL United States
- ARMP United States
- Employees
- CCEL N/A
- ARMP N/A
- Industry
- CCEL Managed Health Care
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEL Health Care
- ARMP Health Care
- Exchange
- CCEL Nasdaq
- ARMP Nasdaq
- Market Cap
- CCEL 51.9M
- ARMP 52.1M
- IPO Year
- CCEL 1997
- ARMP N/A
- Fundamental
- Price
- CCEL $5.62
- ARMP $1.42
- Analyst Decision
- CCEL Strong Buy
- ARMP Strong Buy
- Analyst Count
- CCEL 1
- ARMP 1
- Target Price
- CCEL $8.50
- ARMP $7.00
- AVG Volume (30 Days)
- CCEL 11.9K
- ARMP 23.9K
- Earning Date
- CCEL 04-15-2025
- ARMP 05-06-2025
- Dividend Yield
- CCEL 4.59%
- ARMP N/A
- EPS Growth
- CCEL N/A
- ARMP N/A
- EPS
- CCEL 0.01
- ARMP N/A
- Revenue
- CCEL $32,102,750.00
- ARMP $5,174,000.00
- Revenue This Year
- CCEL $2.21
- ARMP $8.43
- Revenue Next Year
- CCEL $0.98
- ARMP N/A
- P/E Ratio
- CCEL $603.61
- ARMP N/A
- Revenue Growth
- CCEL 2.33
- ARMP 14.24
- 52 Week Low
- CCEL $4.96
- ARMP $0.90
- 52 Week High
- CCEL $9.50
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- CCEL 42.26
- ARMP 51.42
- Support Level
- CCEL $5.37
- ARMP $1.25
- Resistance Level
- CCEL $5.93
- ARMP $1.43
- Average True Range (ATR)
- CCEL 0.51
- ARMP 0.12
- MACD
- CCEL 0.04
- ARMP 0.06
- Stochastic Oscillator
- CCEL 46.81
- ARMP 98.11
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.